You are here

Science

Ebola Lying in Wait

NEW YORK TIMES by Pam Belluck and William J. Broad     April 20, 2015

A growing body of scientific clues — some ambiguous, others substantive — suggests that the Ebola virus may have lurked in the West African rain forest for years, perhaps decades, before igniting the deadly epidemic that swept the region in the past year, taking more than 10,000 lives.

Around 2004 at a government hospital in Kenema, Sierra Leone, a team of American scientists and West African medical personnel found what appeared to be Ebola antibodies in nearly 9 percent of blood samples. Credit Carl De Souza/Agence France-Presse — Getty Images

General Topic Tags: 
Problem, Solution, SitRep, or ?: 

Ebola Analysis Finds Virus Hasn't Become Deadlier, Yet

ICT  INFECTION CONTROL TODAY                                                                  April 14, 2015
(Scroll down for full study)
Research from the University of Manchester using cutting-edge computer analysis reveals that despite mutating, Ebola hasn’t evolved to become deadlier since the first outbreak 40 years ago. The surprising results demonstrate that while a high number of genetic changes have been recorded in the virus, it hasn’t changed at a functional level to become more or less virulent.

The findings, published in the journal Virology, demonstrate that the much higher death toll during the current outbreak, with the figure at nearly 10,500, isn’t due to mutations/evolution making the virus more deadly or more virulent.

As professor Simon Lovell from the Faculty of Life Sciences explains.... What we found was that whilst Ebola is mutating, it isn’t evolving to the point of adapting to become more or less virulent. The function of the virus has remained the same over the past four decades which really surprised us. Unfortunately this does mean the Ebola virus that has now emerged on several occasions since the 1970s will very probably do so again.”

General Topic Tags: 
Problem, Solution, SitRep, or ?: 

Yes, We Were Warned About Ebola

NEW YORK TIMES OP-ED  By BERNICE DAHN, VERA MUSSAH and CAMERON NUTT   April 7, 2015               
MONROVIA, Liberia — The conventional wisdom among public health authorities is that the Ebola virus, which killed at least 10,000 people in Liberia, Sierra Leone and Guinea, was a new phenomenon, not seen in West Africa before 2013. (The one exception was an anomalous case in Ivory Coast in 1994, when a Swiss primatologist was infected after performing an autopsy on a chimpanzee.)

General Topic Tags: 
Problem, Solution, SitRep, or ?: 

Ebola rapid diagnostic kit developed by UK scientists in Sierra Leone

Doctors says the kit, if approved by health authorities, could transform the admissions process with its capacity to deliver results within 20 minutes

THE GUARDIAN    by Lisa O'Carroll                              March 29, 2015

A rapid Ebola diagnostic kit similar to a pregnancy kit has been developed by British military scientists and NHS medics in Sierra Leone.

Health care workers prepare to entering a high risk zone at an Ebola virus clinic in Sierra Leone, where the diagnostic kit has been undergoing tests. Photograph: Michael Duff/AP

It can be administered at the bedside and return its first results within 20 minutes, slashing dramatically the normal 24-hour turnaround for lab results.

General Topic Tags: 
Problem, Solution, SitRep, or ?: 

The tail of the epidemic and the challenge of tracing the very last Ebola case

EUROSURVEILLANCE  by  K. Kaasik-Aaslav and  D. Coulombier                                   March 26, 2015

Upon entering what seems to be the tail of the epidemic and, as in any such moment, the ‘Ebola endgame’ strategy requires adaptation to the heterogeneity of the epidemiological situation. The tools for EVD control need to be fine-tuned and the commitment from the teams supporting local authorities in affected countries needs to be sustained.

While the pressure on clinical and laboratory expertise gradually decreases, the demand shifts towards field epidemiologists to assist local public health experts and support community workers to engage in active surveillance and to monitor remaining transmission chains in affected communities.

General Topic Tags: 
Problem, Solution, SitRep, or ?: 

Laboratory support during and after the Ebola virus endgame: towards a sustained laboratory infrastructure

EUROSURVEILLANCE by I. Goodfellow, C. Reusken, and M. Koopmans  

  March 26, 2015                                                              

The Ebola virus epidemic in West Africa is on the brink of entering a second phase in which the (inter)national efforts to slow down virus transmission will be engaged to end the epidemic. The response community must consider the longevity of their current laboratory support, as it is essential that diagnostic capacity in the affected countries be supported beyond the end of the epidemic.

The emergency laboratory response should be used to support building structural diagnostic and outbreak surveillance capacity.

Problem, Solution, SitRep, or ?: 

Ebola pioneer, stem cell researcher honoured with Canada Gairdner Awards

CANADIAN PRESS                                                                                March 25, 2015
One of the co-discoverers of the Ebola virus and a leading Canadian stem cell researcher are among this year's winners of the prestigious Canada Gairdner Awards.

Dr. Peter Piot is the recipient of the Canada Gairdner Global Health Award, recognizing his work on the discovery of the Ebola virus in 1976 and his leadership in the global response to the HIV-AIDS epidemic.

Dr. Janet Rossant, chief of research at Toronto's Hospital for Sick Children, is the recipient of the 2015 Canada Gairdner Wightman Award, which honours a Canadian who has demonstrated outstanding leadership in medicine and medical science.

Five international scientists are also being honoured with Canada Gairdner Awards, two each from the United States and Japan and one from Switzerland....

Dr. Peter Piot won the 2015 Canada Gairdner Global Health Award in recognition of his work on the discovery of the Ebola virus in 1976 and his leadership in the global response to the HIV-AIDS epidemic. (David Azia/Associated Press)

Red complete story.

General Topic Tags: 
Problem, Solution, SitRep, or ?: 

Ebola virus not mutating as quickly as thought

SCIENCE NEWS  by Ashley Yaeger                                                      March 26, 2015

(Scroll down for full study.)

The virus causing the current Ebola epidemic in West Africa is not evolving as quickly as some scientists had suggested.

REGULAR RATE  A genetic analysis suggests that the Ebola virus, shown here in orange, is not evolving as fast as expected.

In a paper last August, researchers reported that the virus (Zaire ebolavirus) was altering its genes almost twice as fast as it had during previous Ebola outbreaks in Central Africa (SN: 9/20/14, p. 7). However, a new genetic analysis shows that the virus is mutating at roughly the same rate as in past outbreaks, researchers report online March 26 in Science. The finding suggests the virus has not become more virulent or transmissible during the West Africa outbreak.

Problem, Solution, SitRep, or ?: 

Vaccines Face Same Mistrust That Fed Ebola

NEW YORK TIMES  by and         March 14, 2015

MONROVIA, Liberia — West Africa’s Ebola epidemic may be waning, but another outbreak in the future is a near certainty, health officials say.

Problem, Solution, SitRep, or ?: 

New Ebola drug trial starts in Sierra Leone

SCIENCE By Kai Kupferschmidt                                                                       March 11, 2015

Researchers in Sierra Leone today started a new phase II trial of an experimental drug in Ebola patients. The first participant received an injection of the therapeutic, called TKM-Ebola, this morning at an Ebola treatment unit in Kerry Town. The trial may expand to other sites; the study team hopes to have an answer fast so that it can either move on to another drug or start a phase III study of TKM-Ebola.

Produced by Tekmira Pharmaceuticals in Burnaby, Canada, TKM-Ebola is made of synthetic, small interfering RNAs packaged into lipid nanoparticles. The RNAs target three of Ebola’s seven genes, blocking the virus’s replication. TKM-Ebola has been shown to work well in monkeys; the efficacy trial in humans is only starting now because there was not enough of the drug available earlier. Also, the RNAs have been adapted to the strain circulating at the moment.

The study does not have a placebo arm; all patients at the trial site are eligible for the drug, and researchers hope to determine whether it works by comparing them with patients treated elsewhere.

Country / Region Tags: 
Problem, Solution, SitRep, or ?: 

Pages

Subscribe to Science
howdy folks